ValuEngine Downgrades ZEALAND PHARMA/S (NASDAQ:ZEAL) to Sell

ZEALAND PHARMA/S (NASDAQ:ZEAL) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, ValuEngine reports.

Several other equities analysts have also recently weighed in on the company. Guggenheim began coverage on ZEALAND PHARMA/S in a report on Thursday, September 19th. They issued a “buy” rating for the company. Morgan Stanley raised their price objective on ZEALAND PHARMA/S from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Monday, August 19th. Needham & Company LLC set a $32.00 price objective on ZEALAND PHARMA/S and gave the company a “buy” rating in a report on Wednesday, September 18th. Zacks Investment Research restated a “sell” rating on shares of ZEALAND PHARMA/S in a report on Saturday, September 28th. Finally, TheStreet cut ZEALAND PHARMA/S from a “c” rating to a “d+” rating in a report on Friday, August 16th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $27.33.

Shares of NASDAQ ZEAL traded up $1.36 during mid-day trading on Wednesday, hitting $24.95. The company had a trading volume of 2,350 shares, compared to its average volume of 9,560. The company has a market capitalization of $747.13 million, a PE ratio of 8.32 and a beta of 2.05. The firm has a 50-day simple moving average of $22.76 and a two-hundred day simple moving average of $21.04. ZEALAND PHARMA/S has a one year low of $11.51 and a one year high of $28.85.

ZEALAND PHARMA/S (NASDAQ:ZEAL) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.10). The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $7.50 million. On average, sell-side analysts forecast that ZEALAND PHARMA/S will post -2.76 earnings per share for the current year.

An institutional investor recently bought a new position in ZEALAND PHARMA/S stock. Susquehanna International Group LLP purchased a new position in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 15,348 shares of the company’s stock, valued at approximately $331,000. 9.07% of the stock is owned by hedge funds and other institutional investors.

ZEALAND PHARMA/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

See Also: Understanding dividend yield and dividend payout ratio

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.